文献速递脊柱关节炎

甲氨蝶呤联合乌司奴单抗对比乌司奴单抗单药治疗活动性银屑病关节炎患者(MUST):一项随机、多中心、安慰剂对照、3b期、非劣效性试验

Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.
PubMed 文献 · Lancet Rheumatol · 2023-01-01

MUST 3b期非劣效性试验在德国22个中心纳入173例活动性银屑病关节炎患者,随机接受乌司奴单抗联合甲氨蝶呤或安慰剂。第24周乌司奴单抗联合安慰剂在DAS28上非劣于联合甲氨蝶呤(2.9 vs 3.1),分层Mann-Whitney估计值0.5426(95%CI 0.4545-0.6307),第52周同样非劣效。作者认为无证据支持起始乌司奴单抗时加用或维持甲氨蝶呤。

要点

  • 第24周乌司奴单抗联合安慰剂在DAS28上非劣于联合甲氨蝶呤(2.9 vs 3.1)。
  • 第52周乌司奴单抗联合安慰剂同样达到DAS28非劣效。
  • 严重不良事件在安慰剂组7例(9%)、甲氨蝶呤组8例(9%),无死亡。

核心结论

  • 乌司奴单抗抑制IL-12和IL-23是银屑病关节炎的有效治疗,不依赖于甲氨蝶呤的使用;基于DAS28,联用甲氨蝶呤未增加乌司奴单抗的疗效。
  • 基于这些数据,无证据支持在活动性银屑病关节炎患者起始乌司奴单抗时加用或维持甲氨蝶呤。

研究设计与样本

  • 研究者发起的随机、多中心、安慰剂对照、3b期非劣效性试验,在德国22个中心进行。
  • 2017年1月24日至2021年4月12日筛选186例活动性银屑病关节炎患者,173例(93%)入组并1:1随机接受开放标签乌司奴单抗联合盲法甲氨蝶呤(n=88)或安慰剂(n=85)。
  • 84例基线正在接受甲氨蝶呤,89例既往未接受甲氨蝶呤治疗;166例(96%)患者(甲氨蝶呤组87例、安慰剂组79例)纳入第24周安全性和疗效分析(69例[42%]女性;97例[58%]男性;平均年龄48.2岁[SE 1.1])。
  • 主要结局为第24周乌司奴单抗单药(乌司奴单抗联合安慰剂)对比乌司奴单抗联合甲氨蝶呤的平均DAS28非劣效性,按既往甲氨蝶呤治疗分层;关键次要分析为第52周DAS28非劣效性。
  • 主要分析基于分层van Elteren检验,α为2.5%,非劣效界值为12.5%(Mann-Whitney估计值)。

主要发现

  • 第24周DAS28:乌司奴单抗联合安慰剂2.9(SD 1.31)vs 乌司奴单抗联合甲氨蝶呤3.1(1.42);分层Mann-Whitney治疗比较估计值为0.5426(95%CI 0.4545-0.6307)。
  • 第52周乌司奴单抗联合安慰剂在DAS28上同样观察到非劣效。
  • 严重不良事件:乌司奴单抗联合安慰剂组7例(9%)vs 乌司奴单抗联合甲氨蝶呤组8例(9%);无特定严重不良事件影响超过1例患者,无死亡。

关键数值与推荐

  • 非劣效界值为12.5%(Mann-Whitney估计值),α为2.5%。
  • 第24周DAS28分层Mann-Whitney估计值0.5426(95%CI 0.4545-0.6307)。
  • 第52周DAS28非劣效性同样成立(原文未报告具体数值)。

临床怎么用

  • 作者认为,基于这些数据,无证据支持在活动性银屑病关节炎患者起始乌司奴单抗时加用或维持甲氨蝶呤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of methotrexate in combination with biological agents in patients with psoriatic arthritis remains unclear. The MUST phase 3b trial aimed to compare the efficacy of ustekinumab plus placebo with ustekinumab plus methotrexate in patients with active psoriatic arthritis. METHODS: In this investigator-initiated, randomised, multicentre, placebo-controlled, phase 3b non-inferiority trial done in 22 centres in Germany, patients with active psoriatic arthritis received open-label ustekinumab and were randomly assigned (1:1) to masked concomitant therapy with placebo or methotrexate (ongoing or new). The primary outcome was non-inferiority of mean Disease Activity Score-28 joints (DAS28) at week 24 for ustekinumab monotherapy (ustekinumab plus placebo) versus ustekinumab combination therapy (ustekinumab plus methotrexate), stratified by previous methotrexate treatment. The key secondary analysis was non-inferiority of DAS28 at week 52. The primary analysis was based on a stratified van Elteren test with an α of 2·5% and a non-inferiority margin of 12·5% by Mann-Whitney estimator. Adverse events and serious adverse events were assessed. This study is registered with ClinicalTrials.gov, NCT03148860. FINDINGS: Between Jan 24, 2017, and April 12, 2021, 186 patients with active psoriatic arthritis were screened, of whom 173 (93%) patients were enrolled and randomly assigned (1:1) to receive concomitant methotrexate therapy (n=88) or placebo (n=85). 84 patients were receiving methotrexate at baseline, and 89 patients had no previous methotrexate treatment. 166 (96%) patients (87 in the ustekinumab plus methotrexate group and 79 in the ustekinumab plus placebo group) were included in the safety and efficacy analyses at week 24 (69 [42%] female; 97 [58%] male; mean age 48·2 years [SE 1·1]). Ustekinumab plus placebo was non-inferior to ustekinumab plus methotrexate in DAS28 at week 24 (2·9 [SD 1·31] vs 3·1 [1·42]); the stratified Mann-Whitney estimator for treatment comparison was 0·5426 (95% CI 0·4545-0·6307). Non-inferiority for ustekinumab plus placebo was also observed in DAS28 at week 52. Serious adverse events occurred in seven (9%) patients in the ustekinumab plus placebo group and eight (9%) patients in the ustekinumab plus methotrexate group. No specific serious adverse events affected more than one patient, and there were no deaths. INTERPRETATION: Interleukin (IL)-12 and IL-23 inhibition with ustekinumab is an effective treatment for psoriatic arthritis independent of methotrexate use; concomitant methotrexate did not increase efficacy of ustekinumab (based on DAS28). On the basis of these data, there is no evidence to support the addition or maintainance of methotrexate when initiating ustekinumab in patients with active psoriatic arthritis. FUNDING: Janssen Cilag.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Koehm M, Rossmanith T, Foldenauer AC, et al. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial. Lancet Rheumatol. 2023. PMID: 38251504. doi:10.1016/S2665-9913(22)00329-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。